玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察

目的 探讨玻璃体腔注射康柏西普治疗视网膜静脉阻塞(retinal vein occlusion, RVO)继发黄斑水肿(macular edema, ME)的有效性。 方法 采用前瞻性连续性非对照的临床病例分析。选择2014年9月至2015年2月就诊的RVO继发ME 30例30眼,其中视网膜中央静脉阻塞(central retinal vein occlusion, CRVO)继发的ME 9例9眼,视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)继发的ME 21例21眼。玻璃体腔注射康柏西普治疗3次,随访6个月,观察最佳矫正视力(best corrected visual acuity, BCVA)、黄斑中心凹视网膜厚度(central macular thickness, CMT)。 结果 BRVO患眼治疗前及治疗后6个月BCVA分别为(0.77±0.24)logMAR、(0.27±0.19)logMAR,CMT分别为(596.8±139.6)μm、(272.6±29.2)μm,差异具有显著统计学意义(t=4.483, P<0.05; t=7.189, P<0.05);CRVO患眼治疗前及治疗后6个月BCVA分别为(0.87±0.55)logMAR、(0.43±0.2)logMAR,CMT分别为(647.3±163.6)μm、(393.1±121.5)μm,差异具有显著统计学意义(t=2.288, P<0.05; t=7.189, P<0.05)。 结论 玻璃体腔注射康柏西普是一种治疗RVO继发ME的有效方式。

Intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion

Objective To explore the effects of intravitreal injection of conbercept for macular edema(ME)secondary to retinal vein occlusion(RVO). Methods A prospective, continuity and uncontrolled clinical case analysis was used. Thirty cases(30 eyes)with ME secondary to RVO in our hospital from September 2014 to February 2015 were selected, in which 9 cases(9 eyes)were central retinal vein occlusion(CRVO)and 21 cases(21 eyes)were branch retinal vein occlusion(BRVO). All cases were treated with intravitreal injection of conbercept for 3 times and followed up for 6 months. Best corrected visual acuity(BCVA)and central macular thickness(CMT)were observed. Results In patients with BRVO, mean BCVA before treatment and 6 months after treatment were(0.77±0.24)logMAR,(0.27±0.19)logMAR, and CMT were(596.8±139.6)μm,(272.6±29.2)μm, respectively, the difference has statistical significance(t=4.483, P<0.05; t=7.189, P<0.05). In patients with CRVO, mean BCVA before treatment and 6 months after treatment were(0.87±0.55)logMAR,(0.43±0.2)logMAR, and CMT were(647.3±163.6)μm,(393.1±121.5)μm, respectively, the difference has statistical significance(t=2.288, P<0.05; t=7.189, P<0.05). Conclusion Intravitreal injections of conbercept is effective for ME secondary to RVO.